Chemomab Therapeutics (NASDAQ:CMMB) Raised to “Outperform” at Oppenheimer

Oppenheimer upgraded shares of Chemomab Therapeutics (NASDAQ:CMMB) from a market perform rating to an outperform rating in a research note published on Monday, MarketBeat reports. Oppenheimer currently has $6.00 price objective on the stock.

Chemomab Therapeutics Stock Performance

Shares of CMMB stock opened at $0.73 on Monday. Chemomab Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $1.89. The company has a market cap of $8.01 million, a PE ratio of -0.37 and a beta of 0.39. The stock’s fifty day moving average price is $0.75 and its two-hundred day moving average price is $0.64.

Chemomab Therapeutics (NASDAQ:CMMB) last released its earnings results on Thursday, March 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14. During the same period in the prior year, the firm posted ($0.72) earnings per share. On average, equities analysts predict that Chemomab Therapeutics will post -1.2 EPS for the current fiscal year.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).